Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Suntinorexton
Другие языки:

    Suntinorexton

    Подписчиков: 0, рейтинг: 0
    Suntinorexton
    Suntinorexton.svg
    Identifiers
    • N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C23H28F2N2O4S
    Molar mass 466.54 g·mol−1
    3D model (JSmol)
    • CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
    • InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1
    • Key:MQDUVMBBJZLFHF-PMACEKPBSA-N

    Suntinorexton (INN) is an experimental orexin receptor agonist. It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.

    See also




    Новое сообщение